I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Robrecht, S.
85
results:
Format
Online (85)
Mediatypes
Articles (Online) (40)
OpenAccess-fulltext (44)
Audio (Online) (1)
Languages
english (82)
german (1)
Sorted by: Relevance
Sorted by: Year
?
1
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LY..:
Al‐Sawaf, O.
;
Robrecht, S.
;
Zhang, C.
...
Hematological Oncology. 41 (2023) S2 - p. 58-60 , 2023
Link:
https://doi.org/10.1002/..
?
2
Safety of acalabrutinib treatment in very old (≥80 y) and/o..:
Simon, F.
;
Ligtvoet, R.
;
Nösslinger, T.
...
Hematological Oncology. 41 (2023) S2 - p. 468-469 , 2023
Link:
https://doi.org/10.1002/..
?
3
A PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCL..:
Kutsch, N.
;
Fink, A. M.
;
Robrecht, S.
...
Hematological Oncology. 41 (2023) S2 - p. 851-853 , 2023
Link:
https://doi.org/10.1002/..
?
4
IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TRE..:
Langerbeins, P.
;
Robrecht, S.
;
Nieper, P.
...
Hematological Oncology. 41 (2023) S2 - p. 56-58 , 2023
Link:
https://doi.org/10.1002/..
?
5
Deep learning can predict presence of TP53 aberrations and ..:
Pachong, S. Mebwe
;
Robrecht, S.
;
Ligtvoet, R.
...
Hematological Oncology. 41 (2023) S2 - p. 305-306 , 2023
Link:
https://doi.org/10.1002/..
?
6
S143: TRANSCRIPTOMIC CHARACTERIZATION OF MRD RESPONSE AND N..:
Al-Sawaf, O.
;
Jin, H. Y.
;
Zhang, C.
...
HemaSphere. 6 (2022) - p. 44-45 , 2022
Link:
https://doi.org/10.1097/..
?
7
P641: RETREATMENT WITH VENETOCLAX AFTER VENETOCLAX, OBINUTU..:
Cramer, P.
;
Fürstenau, M.
;
Giza, A.
...
HemaSphere. 6 (2022) - p. 539-540 , 2022
Link:
https://doi.org/10.1097/..
?
8
P652: MEASURING MINIMAL RESIDUAL DISEASE BEYOND 10-4 THROUG..:
Hengeveld, P.
;
van der Klift, M.
;
Kolijn, P. M.
...
HemaSphere. 6 (2022) - p. 550-551 , 2022
Link:
https://doi.org/10.1097/..
?
9
S148: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRO..:
Al-Sawaf, O.
;
Zhang, C.
;
Robrecht, S.
...
HemaSphere. 6 (2022) - p. 49-50 , 2022
Link:
https://doi.org/10.1097/..
?
10
THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTI..:
Al‐Sawaf, O.
;
Robrecht, S.
;
Stumpf, J.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
11
VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LY..:
Al‐Sawaf, O.
;
Zhang, C.
;
Robrecht, S.
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
12
VENETOCLAX‐OBINUTUZUMAB MODULATES CLONAL GROWTH: RESULTS OF..:
Al‐Sawaf, O
;
Zhang, C
;
Lu, T
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
13
BENDAMUSTINE, FOLLOWED BY OBINUTUZUMAB, ACALABRUTINIB AND V..:
Cramer, P
;
Fürstenau, M
;
Robrecht, S
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
14
GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PL..:
Tausch, E
;
Schneider, C
;
Yosifov, D
...
Hematological Oncology. 39 (2021) S2 - p. , 2021
Link:
https://doi.org/10.1002/..
?
15
Richter transformation in chronic lymphocytic leukemia (CLL..:
Al-Sawaf, O.
;
Robrecht, S.
;
Bahlo, J.
...
Leukemia. 35 (2020) 1 - p. 169-176 , 2020
Link:
https://doi.org/10.1038/..
1-15
